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Abstract 
Background: Studies suggest that children, adolescents, and young adults (AYAs) with advanced 
cancer receive intense end-of-life (EOL) care. This is particularly true for patients with 
hematologic malignancies. Yet, it is unclear who is at highest risk for receiving intense care.  
Methods: We used the Premier Healthcare Database to perform a population-based analysis of 
patients aged 0-39 years at death with hematologic malignancies who died between 2010-2017. 
We defined intense EOL care as: receipt of cardiopulmonary resuscitation (CPR), intubation, 
hemodialysis, or tracheostomy within the last 30 days of life; more than one emergency room 
(ER) visit within the last 30 days of life; receipt of intravenous chemotherapy within the last 14 
days of life; dying in the intensive care unit (ICU); and having a terminal admission of ≥ 30 
days. We used multivariate logistic regression to identify predictors of having more intense EOL 
care (i.e., ≥ 2 intensity indicators). 
Results: The study cohort included 2,069 decedent patients. The most prevalent intensity 
indicators were receiving chemotherapy (51.7%) and being intubated (45.9%). 47.2% of the 
cohort experienced ≥ 2 intensity indicators. In multivariate analyses, compared with those who 
had leukemia, AYAs with Hodgkin lymphoma (odds ratio [OR]=1.50, 95% confidence interval 
[CI]: 1.97, 2.31) and non- Hodgkin lymphoma (OR=1.13, 95% CI: 1.02, 1.49) were more likely 
to receive intense EOL care. Patients treated in larger hospitals were more likely to receive 
intense care (OR: 1.87; 95% CI: 1.18, 2.97). Longer terminal admissions were associated with 
greater intensity of EOL care. 
Conclusion: Children and AYAs in the United States continue to experience intense EOL care. 
Patients treated at larger hospitals and those who have longer terminal admissions are at 
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While cancer in children, adolescents, and young adults (AYAs) is relatively rare, it is the 
leading cause of non-accidental death among children and the leading cause of disease-related 
death among AYAs in the United States (U.S.)1. Hematologic malignancies comprise around 
40% of all new cancer cases diagnosed in children aged 0-14 years (leukemia accounts for 29% 
while lymphomas account for 12%), and leukemia is the second leading cause of cancer death in 
this age group.2 Meanwhile, lymphomas make up 20% of cancer cases among AYAs aged 15-39 
years and leukemia makes up 13%.2 Survival rates have been improving over the years, but the 
grim reality is that an estimated 10-20% of children and AYAs will continue to die of advanced 
illness.3  
 
Unfortunately, research consistently shows that pediatric and AYA patients with advanced 
cancer often receive intensive treatment at the end of life.4-6 Intensive care at the end of life is 
variably defined in the literature but includes measures such as multiple intensive care (ICU) 
admissions, emergency department (ED) visits, receipt of intravenous chemotherapy, and low 
hospice referrals during the last month of life.7,8 The literature also suggests that young adults 
with cancer who are 18-39 years of age are particularly vulnerable to receiving intense care at the 
end of life, as they are caught between the worlds of pediatric and adult medical providers and 
are therefore less likely to access optimal medical and psychosocial services compared to other 
age groups.9 However, little is known about the predictors for intense end-of-life (EOL) care 
patterns among children and AYAs with hematologic malignancies. 
 
Only limited population-based studies have assessed the pattern of EOL care in children and 
AYAs with cancer.4 In California, nearly two-thirds of pediatric patients (0-21 years) and 59% of 
AYAs (15-39 years) dying of cancer experienced intense EOL care.10  Another southern 
California study reported that 68% of AYAs with cancer received intensive EOL care. 
Furthermore, 75% of AYA Medicaid decedents with cancer in New York received at least one 
aspect of intensive EOL care.6 Internationally, nearly 80% of children dying of cancer received 
intense care in Taiwan and Korea11,12, while 41% of children dying of cancer in Ontario, Canada 
received intense EOL care.13  
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Given the theory that a diagnosis of hematologic malignancy may be associated with receiving 
more intense EOL care,10,14-18 it is critical to further examine this particular population to 
determine what factors are associated with this type of care. To fill these knowledge gaps, we 
assessed patterns of EOL care and evaluated the possible factors associated with more intense 
care among a national cohort of patients in the U.S. with hematologic malignancies who span the 






We conducted a population-based retrospective cohort study using the Premier Healthcare 
Database (PHD). The PHD is a U.S. hospital-based, service-level, all-payer database that 
contains comprehensive information on inpatient and hospital-based outpatient encounters from 
geographically diverse hospitals. The database represents approximately 25% of U.S. admissions 
among private and academic hospitals. These hospitals and healthcare systems submit 
administrative, healthcare utilization, and financial data from patient encounters. PHD data 
include: demographics, admission and discharge diagnoses, information on billed services, 
therapeutic services, and patient disposition and discharge health status. The Yale University 





We identified patients aged 0 to 39 years at death who died between January 1, 2010 and March 
31, 2017 (Figure 1). We evaluated a broader age range to fully capture adolescents and young 
adults, whom the National Cancer Institute defines to be aged 15-39 years.19 Death was 
identified according to the following PHD codes: 20 (expired), 40 (expired at home for hospice 
care), 41 (expire in medical facility for hospice), and 42 (expired, place unknown, for hospice). 
These patients also had to have a diagnosis of hematologic malignancy (HM) at their final 
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encounter, which was identified through ICD-9 and ICD-10 codes. These diagnoses were 
ultimately grouped into four categories: Hodgkin lymphoma (ICD-9: 201.xx; ICD-10: C81.xx), 
non-Hodgkin lymphoma (ICD-9: 202.xx; ICD-10: C82.xx – C86.xx), myeloma (ICD-9: 203.xx; 
ICD-10: C90.xx), leukemia (ICD-9: 204.xx – 208.xx, V10.60; ICD-10: C91.xx – C95.xx), and 




Study Population: Children, adolescents, and young adults between 2010 and 2017 who died of 
hematologic malignancy at ages 0-39 years.   
 
Measurements of intense end-of-life care 
 
Earle and colleagues developed an approach to identify a set of measures that could be indicative 
of intense EOL care.8,20,21 According to this approach, intensive care in the last month of life 
includes invasive medical procedures (e.g., mechanical ventilation) and cancer-directed therapies 
(e.g., chemotherapy), multiple hospital and/or ICU admissions, multiple emergency room visits, 
and in-hospital deaths.8 These measures have been used extensively in adults to evaluate EOL 
care patterns, with a goal of improving quality of care.22 While EOL care measures have not 
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been formally developed for the pediatric population, Earle’s measures have been previously 
adopted to identify intense EOL care patterns among children and AYAs with cancer.4,6,10,13,15 
 
For the purposes of this study, indicators of intense EOL care were having more than 1 
emergency room (ER) visit or receiving cardiopulmonary resuscitation (CPR), hemodialysis, 
tracheostomy placement, or intubation/mechanical ventilation in the last 30 days of life; 
receiving intravenous chemotherapy in the last 14 days of life; dying in the intensive care unit 
(ICU); and having a terminal admission of 30 days or greater. ICD-9/ICD-10 and CPT codes 
were used to identify receipt of CPR, intubation/ventilation, chemotherapy, tracheostomy 
placement, and hemodialysis (Appendix: Table 1).23 Chemotherapy receipt, death in ICU, and 
ER admissions were further identified using billing information. We computed the composite 
number of intensity measures received by each patient.  
 
Data for individual patient encounters did not have exact admission days in the PHD; rather, the 
PHD only provided the month and year of admission, along with the calendar quarter (e.g., 
YYYYQMM format). Therefore, intensity measures were tracked by capturing all encounters 
that fell within one month prior to the patient’s final admission (e.g., any encounter between 
January and February 2012). However, billing data included exact service dates. While there 
were no precise indicators for ICU admission, we amassed a list of billing codes that indicated a 
charge master code in the ICU. The charge master code refers to Premier’s process of mapping 
each hospital’s charge items to a standard charge item, such that these charges are coded 
consistently across the entire database.24  
 
Predictor variables of interest 
 
We included candidate variables which are available in our database and have been used in 
research examining EOL care.4,6,10,13,15 Patient sociodemographic variables included age at death, 
gender, race/ethnicity, and insurance type. HM diagnosis was categorized as Hodgkin 
lymphoma, non-Hodgkin lymphoma, myeloma, leukemia, and “other” HM (not otherwise 
specified according to ICD-9/ICD-10 diagnosis codes). The quartiles of the distribution of the 
patients’ length of stay at final admission were used to categorize that particular variable, so as 
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not to over-represent a particular range of days. Location of death was also noted. Hospital-based 




We defined our outcome of interest (i.e., intense EOL care) as receiving 2 or more intensity 
measures, based on previous literature.4 Descriptive statistics were calculated for each 
independent and dependent variable. We used frequency distributions for categorical variables. 
We used the χ2 test to assess the statistical significance of differences between patients who 
received fewer than 2 intensive EOL care measures and patients who received 2 or more 
intensive EOL care measures for categorical variables. For continuous variables, the statistical 
significance of unadjusted differences between groups of patients were evaluated by Student t-
test.  
 
We conducted univariate analyses to determine factors that are significantly associated with 
having ≥ 2 intensity indicators. We also constructed multivariable logistic regression models and 
used backward elimination to produce the final model. All of the independent variables listed 
above were used when building the model, except for location of death due to the nature of this 
dataset and having an over-representation of hospital deaths (99.1%), and age because of the 
stratified analysis. We stratified analyses by age to determine differences in predictors for 
children versus AYAs. Results were presented in odds ratios and 95% confidence intervals.  
 
All significance tests were two-sided with an 𝛼-level of 0.05. Analyses were conducted using 




Characteristic of study population 
The final study cohort included 2,069 patients with a median age of 30 (interquartile range 
[IQR]: 22-35) years (Table 1). These patients were predominantly male (57.2%), died of 
leukemia (43.6%), and received Medicaid (46.0%). The median length of stay at the final 
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admission was 11 (IQR: 2-27) days. Most patients received their care at an urban hospital 
(94.6%), a teaching hospital (58.6%), or a hospital with at least 200 beds (91.5%).  
 
Compared to those with < 2 intensity indicators, patients with ≥ 2 EOL intensity indicators had 
longer length of stay at last admission (p<0.01), were more likely to die in the hospital (p<0.01), 
and receive care at teaching hospitals (p=0.04) and hospitals with at least 500 beds (p<0.01). 
However, patients with ≥ 2 intensity indicators were more likely to be non-Hispanic black 
(p=0.05) and less likely to die of leukemia (p=0.04). 
 
Table 1.  
Characteristics of decedent pediatric and young adult patients with hematologic malignancies in 




Number of intensity indicators 
< 2  
n (%)  
≥ 2  
n (%) 
p 
Age (at death)     
     0 – 14 217 (10.5) 114 (10.4) 103 (10.6) 0.93 
     15 – 39  1852 (89.5) 979 (89.6) 873 (89.4)  
Gender     
     Male 1184 (57.2) 616 (56.4) 568 (58.2) 0.40 
     Female 885 (42.8) 477 (43.6) 408 (41.8)  
Race/Ethnicity     
     Non-Hispanic White 1076 (52.0) 594 (54.0) 482 (49.5) 0.05 
     Non-Hispanic Black 377 (18.2) 178 (16.2) 199 (20.4)  
     Hispanic 51 (2.5) 28 (2.6) 23 (2.4)  
     Other/unknown 565 (27.3) 293 (27.2) 272 (27.7)  
Length of stay at last admission (in days)     
     0 – 2 522 (25.2) 367 (33.6) 155 (15.9) <0.01 
     3 – 11   550 (26.6) 372 (34.0) 178 (18.2)  
     12 – 27  489 (23.6) 62 (5.7) 427 (43.8)  
      ≥ 28 508 (24.6) 292 (26.7) 216 (22.1)  
Location of death     
     Hospital 2050 (99.1) 1075 (98.4) 975 (99.9) <0.01 
     Outside of hospital for hospice care 19 (0.9) 18 (1.6) 1 (0.1)  
Diagnosis     
     Hodgkin lymphoma 134 (6.5) 61 (5.6) 83 (8.5) 0.04 
     Non-Hodgkin lymphoma 421 (20.3) 241 (22.1) 225 (23.1)  
     Myeloma 26 (1.3) 14 (1.3) 12 (1.2)  
     Leukemia 902 (43.6) 548 (50.1) 439 (45.0)  
     Other hematologic malignancies, not otherwise  
          specified 
586 (28.3) 229 (21.0) 217 (22.2) 
 
Insurance Type     
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     Medicaid 943 (45.6) 473 (43.3) 470 (48.2)  0.39 
     Managed Care 680 (32.9) 349 (31.9) 331 (33.9)  
     Other (Indemnity, Charity, Indigent, Medicare) 446 (21.5) 271 (24.8) 175 (17.9)  
Hospital vicinity to city center     
     Urban 1966 (95.0) 1039 (95.1) 927 (95.0) 0.93 
     Rural 103 (5.0) 54 (4.9) 49 (5.0)  
Teaching status     
     Teaching 1262 (61.0) 644 (58.9) 618 (63.3) 0.04 
     Non-teaching 807 (39.0) 449 (41.1) 358 (36.7)  
Hospital size     
     Small, 0-199 beds 156 (7.5) 105 (9.6) 51 (5.2) <0.01 
     Medium, 200 – 499 beds 858 (41.5) 452 (41.4) 406 (41.6)  
     Large, ≥ 500 beds 1055 (50.0) 536 (49.0) 519 (53.2)  
Geographic region     
     Northeast  389 (18.8) 200 (18.3) 189 (19.4) 0.45 
     Midwest  213 (10.3) 103 (9.4) 110 (11.3)  
     West 417 (20.2) 225 (20.6) 192 (19.7)  
     South 1050 (50.8) 565 (51.7) 485 (49.6)  
 
Prevalence of intensive EOL care 
As shown in Figure 1, 77% of patients received at least one measure of intense EOL care. 
Among the 1583 patients who received some form of intense care, 47% experienced two or more 
measures of intense EOL care. The most common intensity measures (Table 2) were receiving 
intravenous chemotherapy in the last 14 days of life (51.7%, n=1069) and being 
intubated/mechanically ventilated in the last 30 days of life (45.9%, n=949). Additionally, in the 
last 30 days of life, 19.4% received CPR, 24% of patients experienced more than 1 ER visit, 
13.7% had hemodialysis, and 7.9% received a tracheostomy placement. Furthermore, 22.3% of 
patients died in the ICU and 21.4% of patients had a terminal admission of 30 days or longer.  
 
Compared to children aged 0-14 years, AYAs were less likely to receive CPR (p<0.01), less 
likely to have more than 1 ER visit (p=0.02), more likely to receive intubation/mechanical 
ventilation (p<0.01), and more likely to receive a tracheostomy placement (p<0.01) in the last 30 
days of life. Furthermore, these patients were more likely to receive chemotherapy in the last 14 
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Table 2. Prevalence of Intensive End-of-Life Care Measures.  








Within 30 days:     
     CPR 402 (19.4) 75 (34.6) 327 (17.7) <0.01 
     > 1 ER visit 497 (24.0) 61 (28.1) 436 (23.5) 0.02 
     Hemodialysis 283 (13.7) 23 (10.6) 260 (14.0) 0.10 
     Intubation/mechanical ventilation 949 (45.9) 84 (38.7) 865 (46.7) <0.01 
     Tracheostomy 164 (7.9) 6 (2.8) 158 (8.5) <0.01 
Within 14 days:     
     Intravenous chemotherapy 1069 (51.7) 79 (36.4) 990 (53.4) <0.01 
Death in ICU 461 (22.3) 81 (37.3) 380 (20.5) 0.04 
Terminal admission ≥ 30 days  433 (21.4) 76 (35.0) 357 (19.3) 0.21 
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Figure 1. Prevalence of (A) total number of intensity indicators received; (B) at least 1 indicator 
received; and (C) at least 2 indicators received. 
 
Factors associated with intensive EOL care 
Univariate logistic regression results suggested that length of stay at last admission (p<0.01), 
Hodgkin lymphoma diagnosis (p<0.01), teaching status of the hospital (p=0.04), and size of the 
hospital (p<0.01) were associated with receiving more intense EOL care (Table 3). For instance, 
patients who had a terminal admission of 12-27 days had 9.31 times the odds of receiving ≥ 2 
intensity measures (95% CI: 4.78, 15.59) compared to those with a shorter length of stay at the 
terminal admission (0 to 2 days). Those with a terminal admission of 28 days or greater had 1.75 
times the odds (95% CI: 1.35, 2.27). Furthermore, patients diagnosed with Hodgkin lymphoma 
had higher odds of receiving more intense care compared with patients diagnosed with some 
form of leukemia (OR: 1.68; 95% CI: 1.16, 2.45). Patients with other diagnoses also tended to 
have higher odds of receiving more intense care, but these differences were not statistically 
significant. Patients treated at a non-teaching hospital had lower odds of receiving more intense 
EOL care (OR: 0.83; 95% CI: 0.70, 0.92). Finally, compared to patients treated at small hospitals 
(0-199 beds), patients treated at medium-sized hospitals (200-499 beds) had 1.85 times increased 
odds of receiving more intense EOL care (95% CI: 1.29, 2.65) while patients treated at large 
hospitals (≥ 500 beds) had 1.99 times increased odds (95% CI: 1.40, 2.85). AYA patients aged 
15-39 were slightly less likely to receive more intense EOL care compared to children aged 0 to 
14 at death, but this was not statistically significant.  
 
Table 3. Unadjusted Associations Between Patient Characteristics and Receipt of Two or More 
Intensive End-of-Life Care Measures  
Characteristic OR (95% CI) p 
Age (at death)   
     0 – 14 1.00  
     15 – 39  0.91 (0.75, 1.21) 0.93 
Gender   
     Male 1.00  
     Female 0.93 (0.78, 1.11) 0.40 
Race   
     Non-Hispanic White 1.00  
     Non-Hispanic Black 1.20 (0.93, 1.56) 0.16 
     Hispanic 0.89 (0.50, 1.57) 0.68 
     Other/Unable to Determine 0.87 (0.71, 1.07) 0.20 
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Length of stay at last admission (in days)   
     0 – 2 1.00  
     3 – 11   1.13 (0.87, 1.47) 0.35 
     12 – 27  9.31 (4.78, 15.59) <0.01 
     ≥ 28  1.75 (1.35, 2.27) <0.01 
Location of Death   
     Hospital 1.00  
     Outside of hospital for hospice care 0.06 (0.01, 0.46) 0.03 
Diagnosis   
     Hodgkin Lymphoma 1.68 (1.16, 2.45) <0.01 
     Non-Hodgkin Lymphoma 1.25 (0.99, 1.58) 0.06 
     Myeloma 1.33 (0.59, 2.99) 0.49 
     Leukemia 1.00  
     Other Hematologic Malignancy 1.35 (1.10, 1.67) <0.01 
Insurance Type   
     Medicaid 1.00  
     Managed Care 1.07 (0.88, 1.29) 0.53 
     Other (Indemnity, Charity, Indigent, Medicare) 0.91 (0.69, 1.20) 0.51 
Hospital vicinity to city center   
     Urban 1.00  
     Rural 1.02 (0.68, 1.51) 0.93 
Teaching status   
     Teaching 1.00  
     Non-teaching 0.83 (0.70, 0.92) 0.04 
Hospital size   
     Small, 0-199 beds 1.00  
     Medium, 200 – 499 beds 1.85 (1.29, 2.65) <0.01 
     Large, ≥ 500 beds 1.99 (1.40, 2.85) <0.01 
Geographic region   
     Northeast  1.00  
     Midwest  1.13 (0.81, 1.58) 0.47 
     West 0.91 (0.72, 1.15) 0.42 
     South 0.90 (0.69, 1.19) 0.47 
 
After backward elimination, the multivariate logistic regression suggested slightly different 
predictors for the two age groups. Among children aged 0-14 years at death, two variables were 
associated with receiving ≥ 2 measures of intense EOL care: length of stay at last admission and 
geographic region of the hospital (Table 4). Specifically, length of stay at last admission 
remained positively associated with intensity of care. Compared to patients who had a terminal 
admission of 0 to 2 days, those who were in the hospital for 12 to 27 days during their final 
admission had 9.98 times the odds of receiving two or more intensive EOL care measures (95% 
CI: 3.64, 17.40). Furthermore, children who were treated in hospitals in the South had much 
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higher odds of receiving intensive EOL care compared to patients who were treated in the 
Northeast (OR: 4.04; 95% CI: 1.18, 8.83).  
 
Among AYAs aged 15-39 years at death, three variables were associated with receiving ≥ 2 
intensity measures at the end of life: length of stay at last admission, diagnosis, and hospital size. 
Like children, patients who had a terminal admission of 12 to 27 days had higher odds of 
receiving more intense EOL care compared to patients with a terminal admission of 0 to 2 days 
(OR: 7.80; 95% CI: 2.83, 14.86). Patients with a terminal admission of ≥ 28 days also had higher 
odds, though the magnitude was lower (OR: 1.79; 95% CI: 1.34, 2.39). Furthermore, AYAs who 
had Hodgkin Lymphoma and non-Hodgkin Lymphoma had higher odds of receiving more 
intense EOL care compared with AYAs who were diagnosed with a form of leukemia (ORs: 1.50 
[95% CI: 1.97, 2.31] and 1.13 [95% CI: 1.02, 1.49], respectively). Finally, patients treated at 
larger hospitals were more likely to receive intense EOL care. Compared to smaller hospitals, 
patients treated at medium-sized hospitals had 1.71 times the odds of receiving ≥ 2 measures of 
intense EOL care (95% CI: 1.18, 2.70), while those treated at large-sized hospitals had 1.87 
times the odds (95% CI: 1.18, 2.97).  
 
Table 4. Adjusted Associations Between Patient Characteristics and Receipt of Two or More 













Length of stay at last admission (in days)       
     0 – 2 1.00  1.00  1.00  
     3 – 11   1.10 (0.84, 1.43) 0.49 1.87 (0.79, 4.46) 0.16 1.08 (0.82, 1.43) 0.57 
     12 – 27  8.63 (4.24, 14.73) <0.01 9.98 (3.64, 17.40) <0.01 7.80 (2.83, 14.86) <0.01 
     ≥ 28 1.70 (1.30, 2.22) <0.01 1.55 (0.72, 3.34) 0.27 1.79 (1.34, 2.39) <0.01 
Diagnosis       
     Hodgkin Lymphoma 1.50 (1.10, 2.29) 0.05 - - 1.50 (1.97, 2.31) 0.03 
     Non-Hodgkin Lymphoma 1.14 (0.88, 1.48) 0.33 - - 1.13 (1.02, 1.49) 0.04 
     Myeloma 1.32 (0.53, 3.30) 0.56 - - 1.33 (0.53, 3.36) 0.54 
     Leukemia 1.00  - - 1.00  
     Other Hematologic Malignancy 1.08 (0.85, 1.37) 0.52 - - 1.08 (0.84, 1.40) 0.53 
Hospital size       
     Small, 0-199 beds 1.00  - - 1.00  
     Medium, 200 – 499 beds 1.61 (1.07, 2.41) 0.02 - - 1.71 (1.18, 2.70) 0.02 
     Large, ≥ 500 beds 1.71 (1.15, 2.55) <0.01 - - 1.87 (1.18, 2.97) <0.01 
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Our study found that a majority (76.5%) of children and AYA decedents with hematologic 
malignancies received at least 1 measure of intensive EOL care, while 47.2% experienced two or 
more. Children and AYAs who had a longer inpatient stay at the last admission were more likely 
to receive 2 or more EOL care measures. Among children aged 0-14 years at death, being treated 
in the South was another significant predictor for receiving 2 or more EOL care measures. 
Among AYAs, having either Hodgkin or non-Hodgkin Lymphoma were predictors for receiving 
more intense care, along with being treated at a larger hospital. 
 
We found that a majority of children and AYA decedents with hematologic malignancies 
received at least 1 measure of intensive EOL care. Similar to our findings, Mack et al. found that 
75% of adolescent and young adult Medicaid decedents (aged 15-39 years) with cancer in New 
York received at least one intensive measure at the end of life.6 Meanwhile, Johnston et al. found 
that only 23% of their cohort of patients aged 0-21 years in California10 and 30% of another 
cohort of patients aged 15-39 years in the same state4 experienced 2 or more intensity indicators, 
compared to our 47.2% across both age groups. These slight variations may be due to differences 
in the individual measures of intense EOL care chosen for analyses, along with differences in 
prevalence for individual measures. For instance, the Mack study reported on both ICU 
admissions and hospitalizations in the last 30 days of life but did not report on specific 
procedures such as mechanical ventilation, as our study had. Both Johnston studies used hospital 
death as an intensity measure, while our study did not due to being largely limited to encounters 
for patients who died in the hospital. Both Johnston studies also included ICU admissions as one 
of the intensive EOL indictors, which were not available in our study.  
 
Geographic region       
     Northeast - - 1.00  - - 
     Midwest - - 1.44 (0.64, 3.24) 0.38 - - 
     West - - 2.36 (0.74, 4.51) 0.15 - - 
     South - - 4.04 (1.18, 8.83) 0.03 - - 
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Our study observed higher percentages of patients receiving chemotherapy and mechanical 
ventilation/intubation than previous studies in the US.4,6 Nearly half of the patients (51.6%) in 
our study received chemotherapy, whereas only 11% AYA Medicaid decedents in the New York 
State6 and 3-4% of pediatric and AYA decedents in California received chemotherapy.4 The two 
California studies further reported that 19.9% and 16.2% of their cohorts experienced mechanical 
ventilation/intubation within 30 days of death,4,10 compared to our 45.9%. The reasons for these 
differences are relatively unclear, though one explanation could be that our study included 
regions of the United States that these other population-based studies in North America had not 
included. Therefore, it is possible that care patterns tend to be more intensive in this region, 
which would need to be validated with further research. Another explanation may be that our 
cohort only included patients with hematologic malignancies, which has previously been found 
to be a predictor for more intensive EOL care among patients with cancer.10,15-17 One population-
based study examining hospital utilization among pediatric patients in the last year of life in the 
U.S. found that 53.3% of patients with malignancies received mechanical ventilation during the 
terminal admission,25 which is consistent with our findings.  
 
Patients in our cohort also experienced higher rates of intensity measures compared to patients in 
Ontario. Among pediatric cancer decedents in Ontario, 7.9% received IV chemotherapy in the 
last 14 days (compared to our 51.6%), 8.6% had more than one ER visit in the last 30 days 
(compared to our 24%), and 16.7% were mechanically ventilated in the last 14 days (compared 
to our 45.9% in the last 30 days).13 Unlike the Ontario study, our study also included young 
adults who may be more likely to receive more intensive care at the end of life compared to 
children and adolescents.26 Other potential explanations for the discrepancy may be differences 
in healthcare systems and physician practice patterns between the U.S. and Canada.  
 
In our study, there was a higher proportion of white patients who received less intense care, and 
a higher proportion of black and unknown race patients receiving more intense care. However, 
our analyses did not suggest a statistically significant difference in EOL care intensity across 
these racial/ethnic groups. Yet, other studies have previously found that black and Hispanic 
patients may be more likely to receive intensive measures at the end of life, so this disparity is 
worth exploring further.27,28 
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Additionally, patients who received intense care were more likely to spend at least 12 days in the 
hospital at the last admission. Like our multivariable analysis suggested, the odds were 
particularly high for those with a terminal length of stay between 12 to 27 days. Theoretically, 
this makes sense, with the hypothesis being that patients who have a lengthier admission are 
likely hospitalized due to having more serious health complications and are exposed to more 
therapeutic, and thus intensive, procedures and regimens. Further research is needed to test this 
hypothesis. Interestingly, the magnitude of risk was lower for patients with a terminal admission 
of 28 days or greater, though they were still at significantly higher risk for receiving more 
intense care compared to patients with a terminal admission of 0 to 2 days. This pattern warrants 
further investigation to determine why the risk peaks at a particular range of days. 
 
Interestingly, our results showed that AYA patients with either Hodgkin or non-Hodgkin 
lymphomas were significantly more likely to receive highly intense EOL care compared to 
patients with leukemia; other forms of hematologic malignancy were not significantly associated 
with intensity of care. Prior studies show that patients with blood cancers are more likely to die 
without hospice.29,30 However, none of these studies evaluate the differences in care that patients 
with lymphomas versus patients with leukemia may experience. Furthermore, diagnosis was not 
a significant predictor for children as it was for AYAs. Further research is needed to examine 
why differences in treatment patterns at the end of life may exist between these two groups.  
 
Additionally, geographic region was a significant predictor for intense care among children but 
not for AYAs. Children treated in the South had higher odds of receiving more intense care 
compared with children treated in the Northeast. This may be because half (50.8%) of the 
hospitals in our database were located in the South, but further research on regional variations in 
care intensity is needed. On the other hand, AYA patients who were treated at larger hospitals 
were more likely to receive more intense care at the end of life, but the same conclusion could 
not be made for children. Morden et al. previously found that patients with cancer who were 
cared for in medium- and large-sized hospitals received more care by almost every measure of 
intense EOL care compared to patients treated in small hospitals.31 These suggest that it may be 
worth further exploring physicians’ patterns of practice in larger hospitals, particularly when it 
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comes to care at the end of life, and compare these patterns to those of physicians in smaller 
hospitals.  
 
A strength of this study was that it was population-based and we were able to link detailed 
clinical data as possible predictors for intense EOL care. Our study also has the advantage of 
being the first to analyze a cohort that includes both pediatric and AYA patients with 
hematologic malignancies across the country and not just a singular state. By conducting an 
analysis with a wider range of patients who we already hypothesized to be at higher risk for more 
intense EOL care due to their diagnoses, we were able to: (a) directly observe potential 
differences in EOL care intensity between the two age groups, and (b) identify predictors to be 
mindful of specifically for patients with hematologic malignancies.  
 
However, our study has limitations to consider. The nature of the PHD dataset restricted our 
analyses to billing and coding data, which come with inherent limitations. For instance, data for 
individual patient encounters did not have exact admission days; rather, we were only given the 
month and year of admission, along with the calendar quarter. Therefore, we cannot guarantee 
that all encounters and intensity measures received in the final 14 and 30 days of life were 
precisely accounted for. Because claims data are dependent on professional ICD coding, it is also 
possible that some diagnoses may have been missed, that there may have been different coding 
patterns across the hospitals represented in the database, and that not all coding may be 
accurate.32 Other important intensity markers, such as hospice use and ICU admissions,8 were 
not available in sufficient detail in the PHD, which may limit our scope of understanding. 
Furthermore, we were limited to patients who died in the hospital because the database did not 
track patients who died at home or any other facility, unless they died somewhere outside the 
hospital for hospice care. Meanwhile, research shows that around 47% of children with cancer 
die in the hospital, 45% die at home, and anywhere from 2% to 10% die in hospice.33 
Additionally, AYAs were heavily represented in our cohort compared to children (89.5% versus 
10.5%, respectively). Therefore, our results may be more generalizable to AYAs than children 
with cancer.  
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Ultimately, it is important to frame the conversation around the public health implications. Dying 
is inevitable, and while there is no one definition of a “good” death, high levels of patient 
distress can surely be characteristic of a “bad” death.34 Our study is suggesting that 47% of 
children and young adults with HM are receiving two or more measures of intense care at the 
end of their lives, which may cause undue suffering.7 Young patients with long terminal hospital 
admissions are at particularly high risk of receiving more intense care, especially if these patients 
are being treated at large hospitals, so physicians should remain mindful in taking measures to 
prevent highly intense care during this time. This could likely come in the form of better 
integrating palliative care and/or hospice care.35-38 Future studies should also validate whether 
these indicators of intense EOL care8 are as applicable to pediatric and young adult patients, 




Many children, adolescents, and young adults with hematologic malignancies are receiving 
intense care at the end of their lives, which may cause undue pain and suffering. Patients who 
have a longer terminal admission, are being treated at larger hospitals, and have Hodgkin 
lymphoma are at particularly high risk. These are factors that medical teams should be mindful 
of when providing care for these patients to ensure that they are not suffering physically, 
emotionally, and financially. Many prior studies have only been conducted in adult populations, 
so it is imperative that more attention be given to children and young adults who are suffering 
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